An Overview of rAAV Vector Product Development for Gene Therapy
The drug product development pathway involves proof-of-concept efficacy studies, toxicology studies, and human clinical trials conducted in preparation for commercialization. For time and financial efficiency, a perspective of clinical use, product licensure, and commercialization is beneficial at the outset. For gene transfer products, an understanding of the unmet need for the disease target, the market and competing products, the vector configuration, patient population profile, organ target, delivery method, and time and resources involved is essential. Addressing these variables leads to interconnected strategies and plans for business and finance, regulatory affairs, product supply, R&D, clinical investigations, and commercial launch. Establishing an organization with experienced personnel who have defined responsibilities, departments that are working together but are independently responsible, a network of consultants and contract organizations, and a high level of communication is essential to ensure the quality of the product and protection of patients and give the highest chance for success.
KeywordsrAAV Vector Adeno-associated virus Product development Gene therapy Manufacturing Quality control Regulatory Commercialization
Conflict of Interest Statement
RS is an inventor on patents related to recombinant AAV technology. RS owns equity in a gene therapy company that is commercializing AAV for gene therapy applications. To the extent that the work in this manuscript increases the value of these commercial holdings, RS has a conflict of interest.
- 8.Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther. 2004;10(2):302–17.CrossRefPubMedGoogle Scholar
- 18.Snyder RO, Xiao X, Samulski RJ, et al. Production of recombinant adeno-associated viral vectors. In: Dracopoli N, Haines J, Krof B, Moir D, Morton C, Seidman C, editors. Current protocols in human genetics. New York: Wiley; 1996. p. 12.1.1–24.Google Scholar
- 34.USFDA. Guidance for Industry, Formal meetings between the FDA and sponsors or applicants. 2009.Google Scholar
- 35.Lenzi RN, Altevogt BM, Gostin LO, editors. Oversight and review of clinical gene transfer protocols: assessing the role of the recombinant DNA advisory committee. Washington, DC; 2014.Google Scholar
- 36.USFDA. Prescription drug user fee rates for fiscal year 2016. Fed Regist. 2015;80(148):46028–32.Google Scholar
- 37.USFDA. Guidance for Industry, expedited programs for serious conditions – drugs and biologics. 2014.Google Scholar
- 38.Field MJ, Boat TF, editors. Rare diseases and orphan products: accelerating research and development. Washington, DC; 2010.Google Scholar
- 45.USFDA. Guidance for Industry (Draft), Fulfilling regulatory requirements for postmarketing submissions of interactive promotional media for prescription human and animal drugs and biologics. 2014.Google Scholar
- 47.Carvalho LS, Vandenberghe LH. Promising and delivering gene therapies for vision loss. Vis Res. 2014. Epub 2014/08/06.Google Scholar
- 52.Burger L, HIirschler B. First gene therapy drug sets million-euro price record. Reuters. 2014.Google Scholar